

Subscribing organizations are encouraged to copy and distribute this table of contents for non-commercial purposes.

Mitochondrial Stress Response Pathways

Held at University of London, UK, 16–17 Dec 2014.

TSP0 as a target for glioblastoma therapeutics Eryn L. Werry, Melissa L. Barron and Michael Kassiou	531–536
Targeting mitochondrial energy metabolism with TSP0 ligands Philipp Gut	537–542
TSP0 is a REDOX regulator of cell mitophagy Jemma Gatliff and Michelangelo Campanella	543–552
<i>Guwiyang Wurra</i> – ‘Fire Mouse’: a global gene knockout model for TSP0/PBR drug development, loss-of-function and mechanisms of compensation studies Ryan J. Middleton, Guo-Jun Liu and Richard B. Banati	553–558
Targeting the 18-kDa translocator protein: recent perspectives for neuroprotection Eleonora Da Pozzo, Chiara Giacomelli, Elisabetta Barresi, Barbara Costa, Sabrina Taliani, Federico Da Settimo Passetti and Claudia Martini	559–565
Structure of the mammalian TSP0/PBR protein Mariusz Jaremko, lukasz Jaremko, Garima Jaipuria, Stefan Becker and Markus Zweckstetter	566–571
Translocator protein: pharmacology and steroidogenesis Andrew Midzak, Barry Zirkin and Vassilios Papadopoulos	572–578
The 18-kDa mitochondrial translocator protein in gliomas: from the bench to bedside Karolina Janczar, Zhangjie Su, Isabella Raccagni, Andrea Anfosso, Charlotte Kelly, Pascal F. Durrenberger, Alexander Gerhard and Federico Roncaroli	579–585
The methodology of TSP0 imaging with positron emission tomography Federico E. Turkheimer, Gaia Rizzo, Peter S. Bloomfield, Oliver Howes, Paolo Zanotti-Fregonara, Alessandra Bertoldo and Mattia Veronese	586–592
TSP0: functions and applications of a mitochondrial stress response pathway Michelangelo Campanella and Federico E. Turkheimer	593–594

The Keap1/Nrf2 Pathway in Health and Disease

Held at Robinson College, Cambridge, UK, 6–8 Jan 2015.

NRF2 and microRNAs: new but awaited relations Svitlana Kurinna and Sabine Werner	595–601
--	---------

The spatiotemporal regulation of the Keap1–Nrf2 pathway and its importance in cellular bioenergetics Albena T. Dinkova-Kostova, Liam Baird, Kira M. Holmström, Colin J. Meyer and Andrey Y. Abramov	602–610
Dual regulation of transcription factor Nrf2 by Keap1 and by the combined actions of β -TrCP and GSK-3 John D. Hayes, Sudhir Chowdhry, Albena T. Dinkova-Kostova and Calum Sutherland	611–620
Dissecting molecular cross-talk between Nrf2 and NF- κ B response pathways Joanna D. Wardyn, Amy H. Ponsford and Christopher M. Sanderson	621–626
Redox-based regulation of neural stem cell function and Nrf2 Lalitha Madhavan	627–631
Interplay between cytosolic disulfide reductase systems and the Nrf2/Keap1 pathway Edward E. Schmidt	632–638
Keap1/Nrf2 pathway in the frontiers of cancer and non-cancer cell metabolism Dionysios V. Chartoumpekis, Nobunao Wakabayashi and Thomas W. Kensler	639–644
Dysregulation of the Keap1–Nrf2 pathway in cancer Hanna M. Leinonen, Emilia Kansanen, Petri Pölönen, Merja Heinäniemi and Anna-Liisa Levonen	645–649
Sustained NRF2 activation in hereditary leiomyomatosis and renal cell cancer (HLRCC) and in hereditary tyrosinemia type 1 (HT1) Ivraj Singh Sandhu, Nicholas James Maksim, Eva Alice Amouzougan, Bryce Wilson Gallion, Anthony L.J. Raviele and Aikseng Ooi	650–656
Value of monitoring Nrf2 activity for the detection of chemical and oxidative stress Fiona E. Mutter, B. Kevin Park and Ian M. Copple	657–662
Nrf2 as a master regulator of tissue damage control and disease tolerance to infection Miguel P. Soares and Ana M. Ribeiro	663–668
Frequency modulated translocational oscillations of Nrf2, a transcription factor functioning like a wireless sensor Mingzhan Xue, Hiroshi Momiji, Naila Rabbani, Till Bretschneider, David A. Rand and Paul J. Thornalley	669–673
Peptide and small molecule inhibitors of the Keap1–Nrf2 protein–protein interaction Geoff Wells	674–679
Molecular mechanisms of Nrf2 regulation and how these influence chemical modulation for disease intervention Bryan Harder, Tao Jiang, Tongde Wu, Shasha Tao, Montserrat Rojo de la Vega, Wang Tian, Eli Chapman and Donna D. Zhang	680–686
The Keap1/Nrf2 pathway in health and disease: from the bench to the clinic Maria A. O’Connell and John D. Hayes	687–689

New Perspectives in Thrombosis, Haemostasis and Vascular Biology

Held at University College Dublin, Ireland, 13–14 Nov 2014.

- Engineering activated protein C to maximize therapeutic efficacy
Louise M. Quinn, Clive Drakeford, James S. O'Donnell and Roger J.S. Preston **691–695**
- Elevated venous thromboembolism risk in preeclampsia: molecular mechanisms and clinical impact
Karl Egan, Barry Kevane and Fionnuala Ní Áinle **696–701**
- The blood–brain barrier endothelium: a target for pro-inflammatory cytokines
Keith D. Rochfort and Philip M. Cummins **702–706**
- Novel insights into the regulation of cyclooxygenase-2 expression by platelet–cancer cell cross-talk
Melania Dovizio, Sara Alberti, Angela Sacco, Paloma Guillem-Llobat, Simone Schiavone, Thorsten J. Maier, Dieter Steinhilber and Paola Patrignani **707–714**
- Dysregulation of the endothelium following *Staphylococcus aureus* infection
Steven W. Kerrigan and Cormac McDonnell **715–719**
- Role of chemokine receptors CXCR4 and CXCR7 for platelet function
Madhumita Chatterjee, Dominik Rath and Meinrad Gawaz **720–726**

Metabolic Drivers of Immunity

Held at Aston University, UK, 25 Mar 2015.

- The intestinal immunoendocrine axis: novel cross-talk between enteroendocrine cells and the immune system during infection and inflammatory disease
John J Worthington **727–733**
- CD8⁺ T-cell senescence: no role for mTOR
Sian M Henson **734–739**
- Metabolic signatures linked to macrophage polarization: from glucose metabolism to oxidative phosphorylation
Lisardo Boscá, Silvia González-Ramos, Patricia Prieto, María Fernández-Velasco, Marina Mojena, Paloma Martín-Sanz and Susana Alemany **740–744**
- Manipulating membrane lipid profiles to restore T-cell function in autoimmunity
Kirsty E. Waddington and Elizabeth C. Jury **745–751**
- Liver X receptors in immune cell function in humans
Kirsty E. Waddington, Elizabeth C. Jury and Inés Pineda-Torra **752–757**
- Metabolic regulation of natural killer cells
David K. Finlay **758–762**